UY35298A - Formulación en dispersión sólida de un compuesto antiviral - Google Patents

Formulación en dispersión sólida de un compuesto antiviral

Info

Publication number
UY35298A
UY35298A UY0001035298A UY35298A UY35298A UY 35298 A UY35298 A UY 35298A UY 0001035298 A UY0001035298 A UY 0001035298A UY 35298 A UY35298 A UY 35298A UY 35298 A UY35298 A UY 35298A
Authority
UY
Uruguay
Prior art keywords
compound
formulation
solid dispersion
antiviral compound
dispersed
Prior art date
Application number
UY0001035298A
Other languages
English (en)
Inventor
Zia Vahid
Oliyai Reza
Mogalian Erik
Stefanidis Dimitrios
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of UY35298A publication Critical patent/UY35298A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dispersiones sólidas que comprenden un compuesto con la fórmula donde el compuesto está disperso dentro de una matriz de polímero formada por un polímero farmacéuticamente aceptable, y donde además el compuesto es sustancialmente amorfo. También, composiciones farmacéuticas que comprenden el compuesto y métodos de uso para el compuesto.
UY0001035298A 2013-01-31 2014-01-31 Formulación en dispersión sólida de un compuesto antiviral UY35298A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759310P 2013-01-31 2013-01-31
US201361870721P 2013-08-27 2013-08-27

Publications (1)

Publication Number Publication Date
UY35298A true UY35298A (es) 2014-08-29

Family

ID=50114575

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035298A UY35298A (es) 2013-01-31 2014-01-31 Formulación en dispersión sólida de un compuesto antiviral

Country Status (4)

Country Link
US (1) US20140212487A1 (es)
TW (1) TW201446286A (es)
UY (1) UY35298A (es)
WO (1) WO2014120982A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116087C2 (uk) 2011-09-16 2018-02-12 Гіліад Фармассет Елелсі Композиція для лікування вірусу гепатиту c
EP2797586A1 (en) * 2011-12-29 2014-11-05 AbbVie Inc. Solid compositions comprising an hcv inhibitor
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
KR20140119012A (ko) 2013-01-31 2014-10-08 길리어드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
US20180008624A1 (en) * 2015-02-13 2018-01-11 Sandoz Ag Pharmaceutical Compositions Comprising Ledipasvir And Sofosbuvir
WO2016145269A1 (en) 2015-03-12 2016-09-15 Teva Pharmaceuticals International Gmbh Solid state forms ledipasvir and processes for preparation of ledipasvir
CN104961733B (zh) 2015-07-06 2019-04-09 上海众强药业有限公司 雷迪帕韦晶型及其制备方法
WO2017072714A1 (en) * 2015-10-30 2017-05-04 Lupin Limited Stable ledipasvir premix and process of preparation thereof
LT3541807T (lt) 2016-11-16 2021-12-27 H. Lundbeck A/S Magl inhibitoriaus kristalinė forma
JOP20190108B1 (ar) 2016-11-16 2023-09-17 H Lundbeck As تركيبات صيدلانية
CN109646404B (zh) * 2016-12-15 2022-10-04 华领医药技术（上海）有限公司 葡萄糖激酶激活剂的口服制剂及其制备方法
US10004719B1 (en) 2017-05-30 2018-06-26 Taigen Biotechnology Co., Ltd. Solid dispersion formulation
KR102695132B1 (ko) * 2018-05-31 2024-08-14 후아 메디슨 (상하이) 엘티디. 글루코키나제 활성화제 및 비구아니드 혈당 저하 약물을 함유하는 약제학적 병용물, 조성물, 및 병용 제제, 및 이의 제조 방법 및 용도
WO2021155254A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
US20220378788A1 (en) * 2020-04-30 2022-12-01 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
WO2021222739A1 (en) * 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072991A1 (es) * 2008-08-07 2010-10-06 Schering Corp Formulaciones farmaceuticas de un inhibidor de la enzima proteasa de hcv en una dispersion molecular solida
TW201211047A (en) * 2010-06-10 2012-03-16 Gilead Sciences Inc Methods for treating HCV
EP2797586A1 (en) * 2011-12-29 2014-11-05 AbbVie Inc. Solid compositions comprising an hcv inhibitor
US8969588B2 (en) * 2012-06-05 2015-03-03 Gilead Pharmasset Llc Solid forms of an antiviral compound

Also Published As

Publication number Publication date
TW201446286A (zh) 2014-12-16
US20140212487A1 (en) 2014-07-31
WO2014120982A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
UY35298A (es) Formulación en dispersión sólida de un compuesto antiviral
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
AR095132A1 (es) Formulación en dispersión sólida de un compuesto antiviral
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2017000240A1 (es) Compuestos activos hacia bromodominios
CO7141405A2 (es) Uso de pro-fungicidas de uk-2a para el control de la sigatoka negra
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
CO7240372A2 (es) Formulaciones farmacéuticas tópicas no acuosas
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CR20160400A (es) Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza
ES2620754T3 (es) Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores
PH12016500793A1 (en) Turmeric extract containing soft pastilles
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CR20150096A (es) Formulaciones de trans-clomifeno y usos de los mismas
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
BR112014002372A2 (pt) recuperação de petróleo
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211029